Home / Resource Library / Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study

Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study

Results of a study investigating favezelimab with pembrolizumab for treatment of relapsed Hodgkin.